Immortal time bias in contemporary CDK4/6 inhibitor studies: Evidence from target trial emulation
Journal of Oncology Pharmacy Practice
Published online on February 24, 2026
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
BackgroundObservational studies increasingly inform treatment decisions for CDK4/6 inhibitors in metastatic breast cancer, yet their validity is compromised by immortal time bias, a mechanistic bias that inflates treatment benefits when follow-up begins ...
BackgroundObservational studies increasingly inform treatment decisions for CDK4/6 inhibitors in metastatic breast cancer, yet their validity is compromised by immortal time bias, a mechanistic bias that inflates treatment benefits when follow-up begins ...